ArticleImmunology2017
Programmed death 1 is highly expressed on CD8
Article in Immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 50 citations in OpenAlex.
- Why Is MS a More Frequent Complication of EBV Infection in Females?Immunological reviews · 2026Review
- Confined B-Cell Reconstruction and High T-Cell Clonality Define Clinical Response to Cladribine Treatment.Annals of neurology · 2026Article
- Acute COVID-19 is associated with altered CD8 T-cells indicative of impaired ability to control Epstein-Barr virus reactivation.Medical microbiology and immunology · 2026Article
- Review
- Mechanisms of Epstein-Barr virus-associated autoimmunity: a comparative overview.Frontiers in immunology · 2026Review
- T-Lymphocyte Phenotypic and Mitochondrial Parameters as Markers of Incomplete Immune Restoration in People Living with HIV+ on Long-Term cART.Biomedicines · 2025Article
- Epstein-Barr virus and multiple sclerosis: lesson learned to develop better nonhuman primate models.Experimental & molecular medicine · 2025Review
- Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation.Brain : a journal of neurology · 2025Article
- An in-depth understanding of the role and mechanisms of T cells in immune organ aging and age-related diseases.Science China. Life sciences · 2025Review
- Review of evidence linking exposure to environmental stressors and associated alterations in the dynamics of immunosenescence (ISC) with the global increase in multiple sclerosis (MS).Immunity & ageing : I & A · 2024Review
- Natural Killer Cells and Cytotoxic T Cells: Complementary Partners against Microorganisms and Cancer.Microorganisms · 2024Review
- Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice.Cell communication and signaling : CCS · 2023Review
- Meningeal inflammation as a driver of cortical grey matter pathology and clinical progression in multiple sclerosis.Nature reviews. Neurology · 2023Review
- Case report: Granzyme-B expression by T- and B- cells during severe AQP4-positive Neuromyelitis Optica spectrum disorder with fatal venous thromboembolism outcome.Frontiers in neurology · 2023Article
- Comprehensive Investigations Relationship Between Viral Infections and Multiple Sclerosis Pathogenesis.Current microbiology · 2022Review
- Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis.The Journal of experimental medicine · 2022Article
- Programmed Cell Death Protein 1-Positive CD8Neurology(R) neuroimmunology & neuroinflammation · 2022Article
- CD8International journal of molecular sciences · 2022Review
- Cytotoxic B Cells in Relapsing-Remitting Multiple Sclerosis Patients.Frontiers in immunology · 2022Article
- The Potential for EBV Vaccines to Prevent Multiple Sclerosis.Frontiers in neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growing evidence points to a deregulated response to Epstein-Barr virus (EBV) in the central nervous system of patients with multiple sclerosis (MS) as a possible cause of disease. We have investigated the response of a subpopulation of effector CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.